Assessing Variation in the Cost of Palivizumab for Respiratory Syncytial Virus Prevention in Preterm Infants

PharmacoEconomics Open
Ahva ShahabiWarren Stevens

Abstract

The variability in cost of palivizumab treatment, indicated for prevention of respiratory syncytial virus (RSV) infections in high-risk infants, has not been robustly estimated in prior studies. This study aimed to determine the cost variations of palivizumab from a US payer perspective for otherwise healthy preterm infants born 29-35 weeks gestational age (wGA) using infant characteristics and applied dosing regimens. Fenton Growth Charts were merged with World Health Organization Child Growth Standards to estimate preterm infant growth patterns. The merged growth chart was applied to infants who received palivizumab from a prospective, observational registry to determine future body weight using each infant's wGA and birth weight. Using quarter 3 (Q3) 2016-Q2 2017 vial cost, treatment costs at monthly dosing intervals were estimated using expected weights and averaged by age to derive expected mean 2016-2017 RSV seasonal costs per infant under various dosing scenarios. Given different dosing scenarios (two to five doses), birth month, and growth patterns for preterm infants 29-35 wGA, the estimated average 2016-2017 seasonal cost of palivizumab treatment ranged from $3221 to $12,568. Outpatient-only cost (excluding first dose...Continue Reading

References

May 15, 2003·Pediatric Pulmonology·Curt ParnesUNKNOWN Palivizumab Outcomes Registry Study Group
Nov 8, 2003·Social Science & Medicine·Warren Stevens, Charles Normand
Dec 3, 2004·Pediatrics·Laura E Yount, William T Mahle
Mar 28, 2008·Journal of Perinatology : Official Journal of the California Perinatal Association·M FrogelUNKNOWN Palivizumab Outcomes Registry Group
Feb 6, 2010·PharmacoEconomics·William A PrescottJoseph A Paladino
Feb 1, 2011·Early Human Development·Bernhard Resch, Bosco Paes
Mar 23, 2012·Journal of Medical Economics·Leonard B WeinerParthiv J Mahadevia
Jan 4, 2013·BMC Pediatrics·Elhadi H AburawiAbdul-Kader Souid
Mar 14, 2014·The Pediatric Infectious Disease Journal·Christopher S AmbroseJessie R Groothuis
Jun 20, 2014·Medical Decision Making : an International Journal of the Society for Medical Decision Making·Manuel A EspinozaMark J Sculpher
Jul 30, 2014·Pediatrics·UNKNOWN American Academy of Pediatrics Committee on Infectious Diseases, UNKNOWN American Academy of Pediatrics Bronchiolitis Guidelines Committee
Sep 6, 2014·European Journal of Pediatrics·Rolof G P GijtenbeekElianne J L E Vrijlandt
Apr 7, 2015·Journal of the Pediatric Infectious Diseases Society·Christopher S Ambrose, Kimmie K McLaurin
Apr 17, 2015·American Journal of Perinatology·Edmund F La GammaChristopher S Ambrose

❮ Previous
Next ❯

Citations

May 14, 2020·Viruses·Allison E Norlander, R Stokes Peebles
Dec 2, 2017·Human Vaccines & Immunotherapeutics·Sophie JanetMatthew D Snape
Sep 10, 2019·Cell·Morgan S A GilmanJason S McLellan
Mar 5, 2021·Infectious Diseases and Therapy·Archana ChatterjeeLeonard R Krilov

❮ Previous
Next ❯

Methods Mentioned

BETA
PMA
PMAs

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2022 Meta ULC. All rights reserved